🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

17 recruiting trials

for ALK Gene Mutation

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Pembrolizumab injection A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib NCT06378892Phase 29 sites📍 Aviano📍 Florence📍 Lido di Camaiore Centro di Riferimento Oncologico - Aviano · Tests: Lorlatinib Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221n/a1 site📍 Aurora University of Colorado, Denver Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib NCT06620835Phase 227 sites📍 Brest📍 Caen📍 Chambéry Groupe Francais De Pneumo-Cancerologie · Tests: Blood samples for Hematology, Blood samples for Chemistry, Blood sample for liver function tests, Pregnancy test, Tumou… DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers NCT05770037Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC NCT05681780Phase 11 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Tumor-infiltrating Lymphocytes (TIL), Nivolumab, Cyclophosphamide, Fludarabine, Tumor-infiltrating Lymphocyte Therapy Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study NCT07696832n/a1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: Ivonescimab Injection Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation NCT04322890Phase 21 site📍 Changsha Hunan Province Tumor Hospital · Tests: Osimertinib, Alectinib 150 MG, Crizotinib 250 MG, Savolitinib, Crizotinib., Chemotherapy Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006Phase 1, Phase 21 site📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Alectinib Oral Product Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels NCT05525338Phase 48 sites📍 Villejuif📍 Nijmegen📍 Maastricht University Medical Center Groningen · Tests: Alectinib Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB) NCT05724004NA1 site📍 Stockholm Karolinska University Hospital · Tests: SBRT/SRS/radiation therapy A Study on Exploring the Abscopal Effect Induced by Different Radioimmunotherapy Combination Patterns in the Treatment of Non-Small Cell Lung Cancer With Multiple Metastases NCT06947694Phase 21 site📍 Chongqing Xinqiao Hospital of Chongqing · Tests: chemotherapy + PD-1 inhibitors, chemotherapy + PD-1 inhibitors, chemotherapy + PD-1 inhibitors, chemotherapy + PD-1 inh… A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) NCT05384626Phase 1, Phase 274 sites📍 Orange📍 Sacramento📍 Stanford Nuvalent Inc. · Tests: Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol NCT05722886Phase 2, Phase 327 sites📍 Belfast📍 Birmingham📍 Birmingham Cancer Research UK · Tests: Alectinib, Atezolizumab, Entrectinib, Trastuzumab in combination with pertuzumab, Vemurafenib in combination with cobim… Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases NCT06953843Phase 21 site📍 Chongqing Xinqiao Hospital of Chongqing · Tests: Benmelstobart combined with chemotherapy, Benmelstobart combined with chemotherapy, Benmelstobart combined with chemoth… Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT NCT05236946Phase 31 site📍 Mumbai Tata Memorial Hospital · Tests: Stereotactic radiosurgery/whole brain radiotherapy, Tyrosine kinase inhibitor QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC NCT07330596Phase 21 site📍 Hefei Anhui Provincial Cancer Hospital · Tests: QL1706 combined with Chemotherapy, Chemotherapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy